Simplex Trading
ALNY icon

Simplex Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History

Simplex Trading’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.02M Buy
18,200
+3,300
+22% +$1.12M ﹤0.01% 987
2025
Q4 		$5.92M Sell
14,900
-11,700
-44% -$5.18M ﹤0.01% 1158
2025
Q3 		$12.1M Buy
26,600
+4,300
+19% +$1.75M 0.01% 852
2025
Q2 		$7.27M Sell
22,300
-27,600
-55% -$7.64M ﹤0.01% 1086
2025
Q1 		$13.5M Buy
49,900
+21,000
+73% +$5.4M 0.01% 708
2024
Q4 		$6.8M Sell
28,900
-1,700
-6% -$447K ﹤0.01% 1260
2024
Q3 		$8.41M Sell
30,600
-58,700
-66% -$15.3M ﹤0.01% 1148
2024
Q2 		$21.7M Buy
89,300
+21,900
+32% +$3.46M 0.01% 580
2024
Q1 		$10.1M Sell
67,400
-7,600
-10% -$1.27M 0.01% 1117
2023
Q4 		$14.4M Buy
75,000
+19,500
+35% +$3.32M 0.01% 881
2023
Q3 		$9.83M Buy
55,500
+18,700
+51% +$3.57M 0.01% 936
2023
Q2 		$6.99M Sell
36,800
-34,800
-49% -$6.9M 0.01% 1096
2023
Q1 		$14.3M Buy
71,600
+11,800
+20% +$2.48M 0.01% 729
2022
Q4 		$14.2M Buy
59,800
+35,100
+142% +$7.49M 0.02% 701
2022
Q3 		$4.94M Buy
24,700
+4,100
+20% +$782K 0.01% 1218
2022
Q2 		$3M Sell
20,600
-5,100
-20% -$724K ﹤0.01% 1498
2022
Q1 		$4.2M Sell
25,700
-8,100
-24% -$1.23M ﹤0.01% 1403
2021
Q4 		$5.73M Buy
33,800
+200
+0.6% +$37.2K 0.01% 1123
2021
Q3 		$5.7M Buy
33,600
+100
+0.3% +$18.8K 0.01% 1088
2021
Q2 		$5.68M Buy
33,500
+33,333
+19,960% +$4.88M 0.01% 1072
2021
Q1 		$2.36M Buy
167
+63
+61% +$9.48K ﹤0.01% 1441
2020
Q4 		$1.35M Sell
104
-210
-67% -$28K ﹤0.01% 2181
2020
Q3 		$4.57M Sell
314
-23
-7% -$3.27K 0.01% 927
2020
Q2 		$4.99M Sell
337
-370
-52% -$49.9K 0.01% 856
2020
Q1 		$7.7M Sell
707
-244
-26% -$28.2K 0.01% 504
2019
Q4 		$11M Buy
951
+431
+83% +$43K 0.02% 435
2019
Q3 		$4.18M Buy
520
+355
+215% +$28.1K 0.01% 820
2019
Q2 		$1.2M Sell
165
-208
-56% -$16K ﹤0.01% 1746
2019
Q1 		$3.48M Buy
373
+27
+8% +$2.26K 0.01% 932
2018
Q4 		$2.52M Sell
346
-71
-17% -$5.46K 0.01% 942
2018
Q3 		$3.65M Buy
417
+370
+787% +$37.2K 0.01% 810
2018
Q2 		$462K Sell
47
-46
-49% -$4.56K ﹤0.01% 2536
2018
Q1 		$169K Sell
93
-82
-47% -$10.6K 0.01% 1362
2017
Q4 		$50K Sell
175
-747
-81% -$93.9K ﹤0.01% 2447
2017
Q3 		$69K Buy
922
+633
+219% +$54K ﹤0.01% 2005
2017
Q2 		$32K Buy
289
+217
+301% +$13.9K ﹤0.01% 2806
2017
Q1 		$26K Sell
72
-97
-57% -$4.48K ﹤0.01% 2978
2016
Q4 		$70K Sell
169
-66
-28% -$2.76K ﹤0.01% 1824
2016
Q3 		$26K Buy
235
+21
+10% +$1.48K ﹤0.01% 2694
2016
Q2 		$95K Sell
214
-13
-6% -$819 0.01% 1511
2016
Q1 		$89K Buy
227
+155
+215% +$10.3K 0.01% 1451
2015
Q4 		$115K Sell
72
-1
-1% -$93 0.01% 1242
2015
Q3 		$184K Buy
73
+41
+128% +$4.55K 0.01% 969
2015
Q2 		$17K Sell
32
-43
-57% -$5.14K ﹤0.01% 2601
2015
Q1 		$21K Buy
75
+69
+1,150% +$6.99K ﹤0.01% 2287
2014
Q4 		$5K Buy
+6
New +$556 ﹤0.01% 3052

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Simplex Trading's ALNY Position: Q2 2025 in Review

Simplex Trading sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 6,704 shares — an estimated $1.86M sold.

Simplex Trading first reported a position in ALNY in Q4 2014 and held it in 26 quarters. The position peaked at $2.75M in Q1 2023. 653 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

  • Simplex Trading reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Simplex Trading sold 6,704 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $1.86M.
  • Simplex Trading first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 26 quarters.
  • Simplex Trading's Alnylam Pharmaceuticals position peaked at $2.75M in Q1 2023.
  • 653 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Simplex Trading's 13F filing for Q2 2025, filed 5 Aug 2025.